GLOW 70mg

Each lot of GLOW is analyzed to confirm the identity and purity of its constituent peptides:

• Reversed-phase HPLC for component purity (target ≥99% per peptide; lot-specific values reported on the COA).
• Mass spectrometry (MS) for identity confirmation of each component against its expected molecular mass.
• Certificate of Analysis (COA) issued per lot, documenting component ratios, measured purity, and identity data.

Reference identifier for one component: GHK-Cu, CAS 49557-75-7 (tripeptide form). CAS identifiers for BPC-157 and TB-500, exact blend ratio, and net peptide content are reported as lot-specific values on the COA.

These analyses are analytical characterizations of identity and purity only. They do not constitute a representation of safety, efficacy, or fitness for any human or therapeutic application. For research use only, not for human use.

A Certificate of Analysis is available per production lot, documenting HPLC purity and mass-spectrometry identity confirmation.

View Certificates of Analysis →

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

References to clinical phases/studies describe the compound in independent third-party literature (e.g., ClinicalTrials.gov, PubMed) and do not represent claims, testing, or approval by NYsub Peptides.

GLOW is a proprietary multi-component blend, not a single molecule. It is composed of three distinct peptides that have each been characterized separately in the third-party scientific literature. Because it is a blend, no independent study phase, efficacy data, or regulatory designation exists for the combined preparation itself; the material below describes the individual components as reported by external investigators.

• GHK-Cu — a copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, first isolated from human plasma and reported in the literature since 1973. It has been studied in preclinical models in the context of extracellular-matrix gene expression and copper transport (CAS 49557-75-7 for the tripeptide).
• BPC-157 — a synthetic 15-amino-acid (pentadecapeptide) sequence derived from a partial sequence of a protein identified in gastric juice. It has been the subject of numerous preclinical (rodent and in vitro) studies examining angiogenic signaling (e.g., VEGFR2 and the Akt–eNOS axis) and tissue-repair pathways. Human data remain limited to a small number of early pilot studies.
• TB-500 — a synthetic fragment corresponding to the actin-binding region of thymosin beta-4 (Tβ4), a ubiquitous 43-amino-acid G-actin–sequestering polypeptide. The actin-binding motif has been characterized in the literature as a site associated with angiogenic activity in laboratory models.

Regarding third-party clinical research on the parent molecule of one component: full-length thymosin beta-4 (developmental code RGN-352, INN “timbetasin”) has been examined by RegeneRx Biopharmaceuticals in registered human studies, including a Phase 2 protocol for acute myocardial infarction listed on ClinicalTrials.gov as NCT01311518. This reflects independent third-party investigation of the full-length parent protein and does not represent testing or approval of GLOW or of TB-500 by NYsub Peptides. The GLOW blend is supplied for research use only. Not for human use.

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

In the published third-party literature, the individual components of this blend have been examined in laboratory and preclinical (non-human) settings, including:

• GHK-Cu — in vitro and preclinical investigation of extracellular-matrix gene expression, copper coordination chemistry, and fibroblast-associated signaling.
• BPC-157 — rodent and cell-based models examining angiogenic signaling pathways (VEGFR2; the Akt–eNOS/nitric-oxide axis) and growth-factor receptor expression in connective-tissue cells.
• TB-500 / thymosin beta-4 — characterization of G-actin sequestration, actin-cytoskeleton dynamics, and endothelial-cell migration and tubule formation in laboratory angiogenesis assays.

These represent distinct, independently studied mechanisms of the separate compounds; no efficacy or synergy of the combined GLOW blend is claimed.

The research directions above are provided for scientific context only and describe studies of the individual compounds by third parties. This product is not for human use, diagnostic use, or therapeutic use.

Store the lyophilized blend at -20°C, protected from light and moisture, avoiding repeated freeze-thaw cycles; refer to the COA for lot-specific stability notes. Stability with bacteriostatic water or another suitable research-grade solvent has been characterized for laboratory reference only. Handle with appropriate PPE. Not for human use.

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

The following peer-reviewed and registry sources describe the individual components and their parent molecules as studied by third parties:

• Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018. PMC6073405.
• Krivic A, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2010. PMID 21030672.
• Philp D, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003. PMID 14500546.
• RegeneRx Biopharmaceuticals. Safety and Efficacy of Injectable Thymosin Beta 4 (RGN-352) for Treating Acute Myocardial Infarction. ClinicalTrials.gov NCT01311518.

These references are provided for scientific context only and are not claims by NYsub Peptides.